Name | Number of supported studies | Average coverage | |
|---|---|---|---|
| oligodendrocyte | 11 studies | 34% ± 13% | |
| adipocyte | 8 studies | 23% ± 6% | |
| macrophage | 7 studies | 26% ± 8% | |
| endothelial cell | 6 studies | 21% ± 5% | |
| microglial cell | 6 studies | 22% ± 5% | |
| oligodendrocyte precursor cell | 5 studies | 24% ± 3% | |
| fibroblast | 4 studies | 25% ± 9% | |
| glutamatergic neuron | 4 studies | 32% ± 9% | |
| hepatocyte | 3 studies | 35% ± 22% | |
| retinal pigment epithelial cell | 3 studies | 22% ± 9% | |
| GABAergic neuron | 3 studies | 38% ± 5% | |
| alveolar macrophage | 3 studies | 22% ± 6% | |
| endothelial cell of lymphatic vessel | 3 studies | 18% ± 2% | |
| monocyte | 3 studies | 22% ± 2% | |
| astrocyte | 3 studies | 30% ± 16% |
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
|---|---|---|---|---|---|---|
| esophagus | 100% | 821.17 | 1445 / 1445 | 100% | 18.82 | 183 / 183 |
| breast | 100% | 845.16 | 459 / 459 | 100% | 14.63 | 1113 / 1118 |
| intestine | 100% | 857.31 | 966 / 966 | 99% | 15.46 | 524 / 527 |
| prostate | 100% | 740.98 | 245 / 245 | 99% | 12.56 | 499 / 502 |
| stomach | 100% | 459.74 | 358 / 359 | 100% | 16.19 | 285 / 286 |
| brain | 100% | 674.09 | 2630 / 2642 | 100% | 11.67 | 703 / 705 |
| uterus | 100% | 1078.06 | 170 / 170 | 99% | 15.94 | 455 / 459 |
| lung | 99% | 616.00 | 573 / 578 | 100% | 14.98 | 1153 / 1155 |
| bladder | 100% | 995.76 | 21 / 21 | 99% | 14.21 | 497 / 504 |
| thymus | 100% | 819.82 | 653 / 653 | 99% | 11.07 | 596 / 605 |
| skin | 100% | 806.08 | 1807 / 1809 | 97% | 18.93 | 458 / 472 |
| kidney | 100% | 531.10 | 89 / 89 | 95% | 9.51 | 860 / 901 |
| ovary | 99% | 710.59 | 179 / 180 | 95% | 8.36 | 409 / 430 |
| adrenal gland | 100% | 1012.69 | 257 / 258 | 94% | 11.72 | 217 / 230 |
| pancreas | 94% | 310.23 | 309 / 328 | 99% | 10.41 | 176 / 178 |
| liver | 99% | 597.44 | 224 / 226 | 86% | 6.81 | 348 / 406 |
| adipose | 100% | 962.39 | 1204 / 1204 | 0% | 0 | 0 / 0 |
| blood vessel | 100% | 1649.79 | 1335 / 1335 | 0% | 0 | 0 / 0 |
| lymph node | 0% | 0 | 0 / 0 | 100% | 12.37 | 29 / 29 |
| spleen | 100% | 879.90 | 241 / 241 | 0% | 0 | 0 / 0 |
| tonsil | 0% | 0 | 0 / 0 | 100% | 17.77 | 45 / 45 |
| ureter | 0% | 0 | 0 / 0 | 100% | 5.13 | 1 / 1 |
| muscle | 100% | 532.37 | 800 / 803 | 0% | 0 | 0 / 0 |
| heart | 99% | 791.33 | 849 / 861 | 0% | 0 | 0 / 0 |
| eye | 0% | 0 | 0 / 0 | 85% | 8.16 | 68 / 80 |
| peripheral blood | 74% | 325.78 | 689 / 929 | 0% | 0 | 0 / 0 |
| abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| GO_0022900 | Biological process | electron transport chain |
| GO_0007624 | Biological process | ultradian rhythm |
| GO_0009897 | Cellular component | external side of plasma membrane |
| GO_0005829 | Cellular component | cytosol |
| GO_0005576 | Cellular component | extracellular region |
| GO_0005886 | Cellular component | plasma membrane |
| GO_0016491 | Molecular function | oxidoreductase activity |
| GO_0003723 | Molecular function | RNA binding |
| Gene name | ENOX2 |
| Protein name | Ecto-NOX disulfide-thiol exchanger 2 (APK1 antigen) (Cytosolic ovarian carcinoma antigen 1) (Tumor-associated hydroquinone oxidase) (tNOX) [Includes: Hydroquinone [NADH] oxidase (EC 1.-.-.-); Protein disulfide-thiol oxidoreductase (EC 1.-.-.-)] ENOX2 protein Ecto-NOX disulfide-thiol exchanger 2 |
| Synonyms | COVA1 |
| Description | FUNCTION: May be involved in cell growth. Probably acts as a terminal oxidase of plasma electron transport from cytosolic NAD(P)H via hydroquinones to acceptors at the cell surface. Hydroquinone oxidase activity alternates with a protein disulfide-thiol interchange/oxidoreductase activity which may control physical membrane displacements associated with vesicle budding or cell enlargement. The activities oscillate with a period length of 22 minutes and play a role in control of the ultradian cellular biological clock. . |
| Accessions | ENST00000370927.5 [Q16206-1] A0A8I5KRI1 ENST00000394363.6 [Q16206-2] ENST00000370935.5 [Q16206-2] A4QPE1 Q32ND0 B1AKF7 ENST00000432489.5 Q16206 ENST00000338144.8 [Q16206-1] ENST00000686943.1 |